Calypte!!! Was seht Ihr als ... Fortsetzung
Seite 46 von 52 Neuester Beitrag: 18.11.03 22:12 | ||||
| Eröffnet am: | 06.10.03 09:50 | von: Kalli2003 | Anzahl Beiträge: | 2.29 |
| Neuester Beitrag: | 18.11.03 22:12 | von: Moneyworks | Leser gesamt: | 61.950 |
| Forum: | Hot-Stocks | Leser heute: | 35 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 43 | 44 | 45 | | 47 | 48 | 49 | ... 52 > | ||||
Hast du den news über Advectus ?
gruß Grenke
sind aber bei der aktuellen mk auch ein klarer übernahmekandidat;)
mfg kram
Dies war die letzte Mitteilung:
Advectus and Immune Announce Nano-Pharmaceutical Project Update
9/4/03
VANCOUVER, B.C., Sep 04, 2003 (PRIMEZONE via COMTEX) --
Advectus Life Sciences Inc. (TSX Venture Exchange:AVX) (Other OTC:AVXSF) announced today that it has acquired an option from Immune Network Ltd. (Pink Sheets:IMMFF) (www.immunenetwork.com) which, if exercised, would give the Company an exclusive worldwide inter
est in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the 'blood-brain barrier'(BBB) with existing drugs.
Under the terms of the agreement executed today, Advectus will commence development and commercialization work on the new nano-pharmaceutical product upon satisfactory completion of its due diligence process. Advectus will pay option fees over a period of up to six months of due diligence, at any time during which it may enter into a worldwide exclusive license on the joint technology. The terms of the license agreement include an upfront licensing fee of CAD$100,000, a milestone payment of CAD$100,000 upon first clinical trial commencement, and in cash / or equity CAD$5,000,000 upon first marketing approval.
The collaborative and licensing agreement will initially focus on a product leveraging Immune Network's Phase 2 clinical trial results in Alzheimer's disease. Preliminary evidence suggests that certain nano-pharmaceutical formulations may improve the potency and safety of dapsone for Alzheimer's disease, an existing drug which is FDA-approved for other indications.
Advectus is a nanotechnology company focused on pharmaceutical formulations that allow existing drugs to penetrate the BBB and reach their intended site of action in the brain to treat major and life-threatening diseases.
The agreement and the exercise of the option may be subject to regulatory approval.
For more information about Advectus Life Sciences Inc., visit the company's Website: http://www.advectuslifesciences.com/
Risk Alerts: CALYPTE BIOMEDICAL CORPORATION (OTC)
Institutional investors have sold more shares of this company than they have purchased. This may indicate Institutional buyers are losing confidence in this stock
Quelle: Reuters Investor, 20.Oct.3
http://reuters.multexinvestor.com/...tsentiment%2fsellalerts%2falert6
Smoky
(in millions)
Shares Purchased 0.0
Shares Sold 0.0
Net Shares Purchased (0.0)
lol
kram
Hop oder Top heute, wer ist noch dabei? Damit ich ein paar Sarge mitbestelle, Zusammensterben ist schön, ekkekekek
die läßt einen nicht los - ich spring ja auch ab 1 Euro raus und rein aber - ich kanns nicht lassen Caly macht einfach süchtig !
Viel Spaß noch !
Calypte Biomedical Corporation Announces 2004 Financial Guidance
Company Expects Revenues of $23 Million to $25 Million and Net Income of Approximately $5 Million
ALAMEDA, Calif. and NEW YORK, Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today financial guidance for its 2004 fiscal year ending December 31, 2004. Based upon its current backlog, the company expects to generate revenues of $23 million to $25 million and net income of approximately $5 million. The company does not expect to pay taxes next year as a result of Net Operating Loss Carryforwards.
"We continue to generate growing interest in our urine HIV-1 EIA," said Tony Cataldo, Calypte Biomedical's Chairman. "In just the last three months, the company has dramatically transformed itself from teetering on the verge of insolvency to a strong and stable concern. We significantly strengthened our balance sheet by raising $12.5 million from Marr Technologies, our strategic partner. This financing has given us the flexibility to pursue many of the international opportunities that will result in significant contracts. We are only now beginning to close relationships with many of the countries in emerging markets. As we enter these new markets, our growth should accelerate even faster."
The company believes most of its revenues and earnings will come from sales of its urine HIV-1 Rapid and EIA products to emerging markets. Recently, Calypte announced that it had received orders from Botswana and China and had initiated testing in Tanzania, Rwanda, Burundi, and Botswana.
Company Expects Revenues of $23 Million to $25 Million and Net Income of Approximately $5 Million
TUESDAY , OCTOBER 21, 2003 08:30 AM
ALAMEDA, Calif. and NEW YORK, Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today financial guidance for its 2004 fiscal year ending December 31, 2004. Based upon its current backlog, the company expects to generate revenues of $23 million to $25 million and net income of approximately $5 million. The company does not expect to pay taxes next year as a result of Net Operating Loss Carryforwards.
"We continue to generate growing interest in our urine HIV-1 EIA," said Tony Cataldo, Calypte Biomedical's Chairman. "In just the last three months, the company has dramatically transformed itself from teetering on the verge of insolvency to a strong and stable concern. We significantly strengthened our balance sheet by raising $12.5 million from Marr Technologies, our strategic partner. This financing has given us the flexibility to pursue many of the international opportunities that will result in significant contracts. We are only now beginning to close relationships with many of the countries in emerging markets. As we enter these new markets, our growth should accelerate even faster."
The company believes most of its revenues and earnings will come from sales of its urine HIV-1 Rapid and EIA products to emerging markets. Recently, Calypte announced that it had received orders from Botswana and China and had initiated testing in Tanzania, Rwanda, Burundi, and Botswana.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
:)
mfg kram
sieht ja nich übel aus,bietet vor allem enormes potential bei weiteren aufträgen:)
mfg kram